Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
Go back to Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 0.58 -0.03 (4.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.61 | 52 Week High | $1.63 | |||
| Open | $0.62 | 52 Week Low | $0.71 | |||
| Day High | $0.62 | P/E | N/A | |||
| Day Low | $0.56 | EPS | $0.00 | |||
| Volume | 636,119 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.72 +3.72 (2.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.00 | 52 Week High | $65.46 | |||
| Open | $129.69 | 52 Week Low | $47.97 | |||
| Day High | $132.80 | P/E | 88.93 | |||
| Day Low | $128.76 | EPS | $1.47 | |||
| Volume | 12,751,081 | |||||
